Schizophrenia is a chronic disease with diverse psychopathology and multiple phases of illness. Consequently, numerous factors must be considered when assessing the benefits of a given treatment over short-and long-term periods. Olanzapine is a typical antipsychotic reported to be effective without producing many of the disabling extrapyramidal adverse effects associated with older, typical antipsychotic drugs. Even though olanzapine is still associated with a known risk of adverse metabolic effects such as weight gain, many clinicians continue to prescribe olanzapine for the treatment of Schizophrenia with the expectation of significant therapeutic efficacy relative to other first-line atypical antipsychotics. This review focuses on the epidemiology, pathogenesis, and treatment of Schizophrenia, with a particular emphasis on the role of olanzapine in its treatment. Genetic variants associated with the therapeutic efficacy and adverse effects of olanzapine are reviewed, and those with the potential to act as clinical predictors of therapeutic response and/or adverse effects are discussed. Finally, recommendations are made for the use of some of these genetic variants in clinical medicine.